- Conference call today, December 19,
2023, 8:30 AM ET to discuss
the license agreement
HOLON, Israel, Dec. 19,
2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)
(TASE: CGEN) a clinical-stage cancer immunotherapy company and a
pioneer in computational target discovery, today announced
that it will host a conference call at 8:30
AM ET today, to discuss the exclusive license agreement with
Gilead announced today, for the development and
commercialization of its anti-IL-18 binding protein program
including COM503, a pre-clinical potential first-in-class high
affinity antibody targeting IL-18 binding protein with potential to
treat multiple tumor types.
Conference Call Details
To access the live conference call by telephone, please dial
1-866-744-5399 from the U.S., or +972-3-918-0644 internationally.
The call will be available via live webcast through Compugen's
website, located at the following link.
Following the live webcast, a replay will be available on the
Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT
component is derived from Compugen's clinical stage anti-TIGIT
antibody, COM902, in Phase 3 development by AstraZeneca through a
license agreement for the development of bispecific and
multispecific antibodies. In addition, the Company's
therapeutic pipeline of early-stage immuno-oncology programs
consists of programs aiming to address various mechanisms of immune
resistance, of which the most advanced program, COM503, is in IND
enabling studies. COM503 is a potential first-in-class, high
affinity antibody which blocks the interaction between IL-18
binding protein and IL-18, thereby freeing natural IL-18 in the
tumor microenvironment to inhibit cancer growth. Compugen is
headquartered in Israel, with
offices in San Francisco, CA.
Compugen's shares are listed on Nasdaq and the Tel Aviv Stock
Exchange under the ticker symbol CGEN.
Company contact:
Yvonne
Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-host-conference-call-to-discuss-exclusive-license-agreement-with-gilead-for-com503-novel-immuno-oncology-pre-clinical-program-harnessing-il-18-biology-302018824.html
SOURCE Compugen Ltd.
